ストックスクリーナーアプリを入手
38.49
0.60%
0.23
前日終値:
$38.26
開ける：
$38.44
24時間の取引高:
157.07K
Relative Volume:
0.48
時価総額：
$1.84B
収益：
-
当期純損益:
$-107.28M
株価収益率:
-14.79
EPS:
-2.6031
ネットキャッシュフロー:
$-80.71M
1週間 パフォーマンス:
+7.39%
1か月 パフォーマンス:
+3.83%
6か月 パフォーマンス:
+25.13%
1年 パフォーマンス:
+243.66%
1日の値動き範囲:
$36.76
$38.65
1週間の範囲:
$33.51
$39.98
52週間の値動き範囲:
$10.51
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Compare RAPP vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
38.49 | 1.83B | 0 | -107.28M | -80.71M | -2.6031 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Strong Buy |
| 2026-02-02 | 開始されました | Wells Fargo | Overweight |
| 2025-11-19 | 開始されました | BTIG Research | Buy |
| 2025-09-16 | 開始されました | Truist | Buy |
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-08 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-07-02 | 開始されました | Jefferies | Buy |
| 2024-07-02 | 開始されました | Stifel | Buy |
| 2024-07-02 | 開始されました | TD Cowen | Buy |
すべてを表示
Rapport Therapeutics Inc (RAPP) 最新ニュース
Rapport Therapeutics (RAPP) director receives 15,200 stock options grant - Stock Titan
[Form 4] Rapport Therapeutics, Inc. Insider Trading Activity - Stock Titan
Rapport Therapeutics (RAPP) director receives 15,200-share stock option grant - Stock Titan
Rapport Therapeutics (RAPP) director granted 15,200 stock options at $35.21 - Stock Titan
Rapport Therapeutics Holds 2026 Annual Shareholder Meeting - TipRanks
Rapport Therapeutics (RAPP) holders elect Class II board, ratify PwC - Stock Titan
Goldman Sachs Group Inc. Buys 579,903 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Precision Trading with Rapport Therapeutics Inc. (RAPP) Risk Zones - Stock Traders Daily
Rapport Therapeutics (RAPP) Edges Higher Amid Tight Trading RangePut Flow Alert - newsline.com
Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative? - Yahoo Finance
Wall Street Firms Raise Rapport Therapeutics Price Targets - sekbernews.id
BTIG and Truist Raise Price Targets for Rapport Therapeutics - HarianBasis.co
BTIG Raises its Price Target on Rapport Therapeutics (RAPP) - Insider Monkey
RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy - TipRanks
5 Stocks That Have the Potential to Rise 1000% - Insider Monkey
Number of shareholders of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
BTIG Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Citizens reiterates Rapport Therapeutics stock rating on competitor trial data - Investing.com
Citizens reiterates Rapport Therapeutics stock rating on competitor trial data By Investing.com - Investing.com Canada
Rapport Therapeutics (RAPP) Q1 2026 Earnings: Narrower Loss Beats Estimates; Stock Holds Steady - newsline.com
Technical Reactions to RAPP Trends in Macro Strategies - Stock Traders Daily
RAPP Q1 2026 Earnings: Narrower Loss Beats Street Estimates as Pre-Revenue Biotech Advances Pipeline - newsline.com
Rapport Therapeutics (RAPP) Holds Steady as Minor Decline Tests Key Support LevelsKeltner Channel - newsline.com
Third Rock sells 836,136 RAPP shares across April–May 2026 (RAPP) - Stock Titan
Rapport Therapeutics Inc. (RAPP) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock GainProduct Revenue Analysis - Newser
RAPP Should I Buy - Intellectia AI
Rapport Therapeutics (RAPP) Gains 2.7% as Price Approaches Key Resistance LevelValue Factor - Newser
RAPP Maintains Buy Rating -- Price Target Raised to $65.00 by BT - GuruFocus
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Rapport Therapeutics to Participate in the Jefferies Global - GlobeNewswire
Biotech firm Rapport slated for Jefferies and Goldman investor talks - Stock Titan
RAPP Assumes Buy Rating with Price Target Raised to $56.00 by Tr - GuruFocus
Truist Financial Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Rapport Therapeutics (RAPP) Stock Today: Drops -1.71%, Key Support at $32.85 2026-05-19Index Put Call - newsline.com
Rapport Therapeutics Inc (RAPP) - MSN
Truist assumes Rapport Therapeutics stock with buy on epilepsy drug By Investing.com - Investing.com Canada
Truist Financial Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $56 - Moomoo
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside - TipRanks
Trading the Move, Not the Narrative: (RAPP) Edition - Stock Traders Daily
Will Narrowing Losses And Per Share Improvement Reframe Rapport Therapeutics' (RAPP) Investment Narrative? - simplywall.st
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
Vanguard Group Inc. Acquires 191,219 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Third Rock Ventures v sells $5.38m in Rapport Therapeutics stock By Investing.com - Investing.com South Africa
Third Rock Ventures v sells $5.38m in Rapport Therapeutics stock - Investing.com
TradingKey - TradingKey
Stifel reiterates Buy on Rapport Therapeutics stock, $56 target By Investing.com - Investing.com Canada
Rapport Therapeutics(RAPP.US) 10% Shareholder Sells US$11.09 Million in Common Stock - Moomoo
Third Rock funds trim Rapport Therapeutics (RAPP) stake under Rule 10b5-1 plan - Stock Titan
Third Rock sells shares of RAPP (NASDAQ: RAPP) under Form 144 - Stock Titan
Swedbank AB Buys Shares of 113,200 Rapport Therapeutics, Inc. $RAPP - MarketBeat
BTIG Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Rapport Therapeutics Inc (RAPP) 財務データ
収益
当期純利益
現金流量
EPS
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):